A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
NCT02094417
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Aplastic Anemia
Interventions
DRUG:
AMG531
Sponsor
Kyowa Kirin Korea Co., Ltd.